ABVC BioPharma obtains waiver from Lind Global on market cap default condition through Feb 2024

ABVC BIOPHARMA, INC.

Lind Global waives any Event of Default for market cap below $12.5M for 10 consecutive days through Feb 23, 2024.
Lind retains conversion rights under Note sections 2.2(a) and 2.2(c)(2)(x), which could result in stock issued at significant discount.
Outstanding principal of Note is $2,754,167; Mandatory Default Amount set at 115% = $3,167,292.05.
If market cap does not increase or further waiver/amendment not obtained, an event of default could materially affect liquidity and operations.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

ABVC BIOPHARMA, INC. amended Letter Agreement with Lind Global Fund II LP (effective 2023-09-12).

Action: amendment
Counterparty: Lind Global Fund II LP
Effective: 2023-09-12

Exact text from the filing

On September 12, 2023, the Company and the Investor entered into a letter agreement (the “Letter Agreement”) pursuant to which the Investor agreed to waive any default, any Event of Default, and any Mandatory Default Amount (each as defined in the Note) associated with the Company’s market capitalization being below $12.5 million for 10 consecutive days through February 23, 2024.

View on SEC.gov

Browse all material agreements →

ABVC BIOPHARMA, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-076241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.